RV-6153
RV-6153 is a potent and selective dual inhibitor of PI3Kδ and PI3Kγ, with IC50 values of 2.5 nM and 28 nM, respectively. RV-6153 dually inhibits PI3Kδ and PI3Kγ, blocking Akt phosphorylation, thereby inhibiting ROS production and cytokine release at the cellular level, and reducing neutrophil and macrophage accumulation in the airways in vivo. RV-6153 can be used in research on chronic obstructive pulmonary disease, asthma, and other inflammatory diseases.
For research use only. We do not sell to patients.
- CAS No.: 1628139-03-6
- Formula: C36H31F4N7O5
- Molecular Weight:717.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
p110δ 2.5 nM (IC50) |
p110γ 28 nM (IC50) |
p110β 4890 nM (IC50) |
p110α >13900 nM (IC50) |
Akt |
IL-4 |
IL-5 |
IL-13 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U-937 | IC50 |
7.4 nM
Compound: 18; RV6153
|
Cytotoxicity against in human U937 cells
Cytotoxicity against in human U937 cells
|
[PMID: 30582813] |
In Vitro
RV-6153 (Compound I) inhibits Zymosan (HY-159069)-induced ROS production in IFNγ (HY-P7025)-pretreated U937 cells (REC50 = 11.8 nM)[1].
RV-6153 (10 μg/mL; 4-24 h) shows no cytotoxicity in U937 cells[1].
RV-6153 selectively inhibits PI3Kδ and PI3Kγ activity in recombinant PI3K enzyme systems, with IC50 values of 2.5 nM and 28 nM, respectively, and shows weak inhibitory effects on PI3Kα and PI3Kβ[1].
RV-6153 inhibits Akt phosphorylation in H2O2- and MCP-1 (HY-P7237)-stimulated macrophage-differentiated U937 cells, with REC50 values of 7.4 nM and 16.5 nM, respectively)[1].
RV-6153 inhibits Cytostim-induced release of IL-4, IL-5, IL-13 (IC50 < 1.4 nM) and IFNγ (IC50 = 13.8 nM) in PBMC[1].
RV-6153 inhibits MCP-1 chemotaxis in THP-1 monocytes (IC50 = 33.9 nM)[1].
RV-6153 inhibits TNFα (HY-P7058)-induced CXCL8 release in COPD-derived neutrophils (IC50 = 2.2 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PMA-differentiated U937 cells
-
Concentration:10 μg/mL
-
Incubation Time:4, 24 h
-
Result:Detected no significant inhibition of cell viability.
In Vivo
RV-6153 (0.05-1 mg/mL; i.t.; single dose; pretreatment 2 h before the last OVA challenge) dose-dependently inhibits eosinophil and neutrophil accumulation in bronchoalveolar lavage fluid in the OVA (HY-W250978)-induced allergic airway inflammation model in BALB/c mice[1].
RV-6153 (0.002-0.2 mg/mL; i.n.; administered before each Poly I:C challenge, 6 times total (twice daily for 3 consecutive days); samples collected 24 h after challenge) significantly inhibits macrophage and neutrophil accumulation in the airways in the Poly I:C (HY-107202)-induced A/J mouse airway inflammation model[1].
RV-6153 (0.02-2 mg/mL; i.n.; once daily for 3 consecutive days; administered after the end of cigarette smoke exposure) inhibited macrophage and neutrophil accumulation and reduced the concentrations of multiple inflammatory biomarkers in a cigarette smoke (CS)-induced airway inflammation model in A/J mice, and exhibited synergistic enhancement when combined with Fluticasone (HY-B0603)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mice and rats were exposed to an aerosol of 0.5 mg/mL (mice) or 0.3 mg/mL (rats) LPS solution for 30 minutes via an ultrasonic nebulizer to induce airway inflammation[1]
-
Dosage:0.05, 0.2, 1.0 mg/mL
-
Administration:i.t.; single dose; pre-treatment 2, 8, or 12 hours prior to LPS challenge
-
Result:Dose-dependently inhibited LPS-induced neutrophil accumulation in the airways of mice and rats.
Reduced neutrophil accumulation by 68% in mice and 73% in rats at a concentration of 1.0 mg/mL administered 2 hours prior.
Demonstrated a long duration of action (significant inhibitory effects were maintained even with a 12-hour pre-treatment).
-
Animal Model:BALB/c mice were sensitized with OVA via intraperitoneal injection on days 0 and 7[1]
-
Dosage:0.05, 0.2, 1 mg/mL
-
Administration:i.t.; single dose; administered 2 h prior to the final OVA
-
Result:Dose-dependently inhibited the accumulation of eosinophils and neutrophils in BALF in the OVA-induced airway inflammation model.
-
Animal Model:A/J mice were intranasally dosed with Poly I:C to induce a viral respiratory inflammation model[1]
-
Dosage:0.002, 0.02, 0.2 mg/mL
-
Administration:i.n.; twice daily for 3 days, administered 2 hours before each Poly I:C challenge; sampled 24 hours after the last challenge
-
Result:Dose-dependently inhibited Poly I:C-induced macrophage and neutrophil accumulation, and its potency was significantly greater than the reference compound (Compound A).
Chemical Information
-
CAS No. 1628139-03-6
-
Molecular Weight 717.68
-
Formula C36H31F4N7O5
-
SMILES
O=C1C=2C(C#CCOCCOCCOC)=CC=CC2N=C(N1CC=3C=CC=CC3C(F)(F)F)CN4N=C(C=5C=C(F)C=C(O)C5)C=6C(=NC=NC64)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- RV-6153
- 1628139-03-6
- RV6153
- RV 6153
- PI3K
- Akt
- Reactive Oxygen Species (ROS)
- Interleukin Related
- CXCR
- COPD
- PI3K delta/gamma inhibitor
- asthma
- atropisomerism
- cell-based screening systems
- cigarette smoke-induced macrophage accumulation
- cigarette smoke-induced neutrophil accumulation
- intracellular pharmacological effects
- poly I:C-induced neutrophil influx
- Inhibitor
- inhibitor
- inhibit